

PMX 205 acetate(514814-49-4 free base)

Chemical Properties

CAS No. :


Formula: C47H66N10O8

Molecular Weight: 899.09

Keep away from moisture

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88).
Targets(IC50)	Complement System
In vitro	PMX 205 (PMX205) group is in between 0.09893 to 0.2465, EP54 group, 0.02724 to 0.1748 and Tamoxifen group, the value recorded in between 0.09880 to 0.2464. For the 48 h plate of incubation time, only two groups of PMX 205 and Tamoxifen show a significant result. The values recorded are in between 0.04987 to 0.3273 and 0.5777 to 0.8551 respectively. For the 72 h plate, only one group shows a significant result, PMX 205 (antagonist group) with the value recorded in between 0.02136 to 0.5322[1].
In vivo	Tg2576 mice are treated with PMX 205 (PMX205) at 20 µg/mL in the drinking water (n=17) from 12 to 15 mo of age, the time frame at which there is a rapid accumulation of amyloid deposits in these animals. Untreated Tg2576 animals (n=11) are used as controls. After 3 mo, animals treated with PMX 205 show significantly less fibrillar plaque load (thioflavine reactivity) than do untreated animals. In 3×Tg mice, PMX 205 also significantly reduces hyperphosphorylated tau (69%)[2].

Solubility Information

Solubility	H2O: 1.13 mg/mL (1.26 mM),Sonication is recommended. DMSO: 60 mg/mL (66.73 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1122 mL	5.5612 mL	11.1224 mL
5 mM	0.2224 mL	1.1122 mL	2.2245 mL
10 mM	0.1112 mL	0.5561 mL	1.1122 mL
50 mM	0.0222 mL	0.1112 mL	0.2224 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. *J Cancer Res Ther.* 2016 Apr-Jun;12(2):590-6.

Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. *J Immunol.* 2009 Jul 15;183(2):1375-83.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481